Hetrazan

(Diethylcarbamazine)

ApprovedSmall molecule

WWyeth-Lederle Vaccines

Hetrazan is one of 9 small molecule programs targeting Onchocerciasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

OnchocerciasisActive, not recruiting

LoiasisActive, not recruiting

OnchocerciasisPreclinical

Active, not recruiting

LoiasisApproved

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Onchocerciasis

#DrugCompanyPhaseTrials

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

8 2

Rifadin

Sanofi

Approved

—3

Cydectin

MMedicines Development for Global Health

Approved

3 4

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—5

Hetrazan

WWyeth-Lederle Vaccines

Approved

1 6

Emodepside

JJennifer Keiser

Phase 2

1 7

Albenza

IImpax Laboratories, LLC

Preclinical

2 8

Bi-Annual CDTI

UUniversiteit Antwerpen

Preclinical

2 9

Praziquantel /kg

OOswaldo Cruz Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 2·NCT01975441·182 enrolled

Azithromycin1 trial

PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

Completed·LLihir Medical Centre·Phase 2·NCT03664063·42 enrolled

Chemotherapy1 trial

Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection

Completed·IIndian Council of Medical Research·Phase 4·NCT02005653·146 enrolled

3 more indications

Onchocerciasis1 trial

Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis

Completed·WWashington University School of Medicine··NCT01905423·17,108 enrolled

Filariasis1 trial

Host Response to Infection and Treatment in the Filarial Diseases of Humans

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00001230·500 enrolled

Unspecified1 trial

Moxidectin for LF, Cote d'Ivoire (DOLF)

Completed·WWashington University School of Medicine·Phase 3·NCT04410406·164 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

HETRAZAN

NDA NDA006459

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Diethylcarbamazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diethylcarbamazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diethylcarbamazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA006459). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wyeth-Lederle Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWyeth-Lederle Vaccines

Hetrazan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphatic Filariasis3 trials

Loiasis2 trials

Drug Therapy1 trial

Azithromycin1 trial

Chemotherapy1 trial

Onchocerciasis1 trial

Filariasis1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News